Research article · 28 Oct 2019
Conference abstract
Indomethacin solid dispersions: Pharmaceutical development
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Indomethacin is a nonsteroidal anti-inflammatory drug which inhibits the cyclo-oxygenase enzyme, in order to reduce the precursors of prostaglandins and thromboxanes formation from arachidonic acid. Many therapeutical and side effects of indomethacin can be produced by the inhibition of prostaglandin synthesis in different tissues, while other actions may also contribute significantly to the therapeutic effect of indomethacin (Delta). It is used to reduce pain/swelling involved in osteoarthritis, rheumatoid arthritis, bursitis, tendinitis, gout, ankylosing spondylitis, and headaches. The drug is described as poorly soluble and highly permeable (Class II) drug. Because water-insoluble drugs often show low absorption and this undesirable physical property may increase the incidence of irritating side effects on the gastrointestinal tract because of a prolonged contact time with the mucosa. Our aim is to increase indomethacin solubility in order to reduce the gastrointestinal damage produced. In order to this, we have studied the solubility of indomethacin at three different pH (1.2; 7.4; 8.4). The best solubility was achieved at pH 8.4 adding sodium laurylsulfate (0,125 mg/mL). Six different formulations were prepared with different ratios of indomethacin and L-HPC (1:0; 1:1; 1:2.5; 1:5; 1:10; 1:20).
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 3 May 2019
Enhancement of dissolution rate of indomethacin by kollicoat IR based solid dispersions
Research article · 19 May 2016
Solid dispersion matrix tablet comprising indomethacin-PEG-HPMC fabricated with fusion and mold technique
Conference abstract · 30 Apr 2021
Optimizing early phase development of amorphous solid dispersion formulation thorough application of modeling tool
Short communication · 2021
Optimizing early phase development of amorphous solid dispersion formulations thorough application of modeling tools
More from this journal
The newest in Pharmaceutica Analytica Acta.
Article · 16 Sep 2026
The Fc Domains in the Monoclonal Antibody and Fusion Protein Significantly Boost the Biocomposite Suspension's Power to Combat Harmful Microorganisms, Enhance Drug Delivery, and Improve Protein Stability
Article · 26 Jun 2026
Green Pathways in Drug Quality Assessment: The Growing Role of Sustainable Pharmaceutical Analytics
Article · 26 Jun 2026
Advanced Single-Cell Signal Analysis: The Role of Ghost Cytometry in Cell Therapy Characterization
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutica Analytica Acta
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Estefania Tascon-Otero”
- BylineArticles whose byline prints “Eva Navarro-Ruiz”
- BylineArticles whose byline prints “Juan J Garcia-Rodriguez”
- BylineArticles whose byline prints “Susana Torrado-Duran”
- BylineArticles whose byline prints “Santiago Torrado-Duran”
- BylineArticles whose byline prints “Covadonga Alvarez-Álvarez”
- BylineArticles whose byline prints “Paloma M de la Torre-Iglesias”

